Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has been filed on behalf of investors who purchased securities of Altimmune, Inc. (“Altimmune”) (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025.
If you have incurred significant losses and want to act as the lead plaintiff in the class action lawsuit or determine your eligibility to receive a potential recovery, please submit your details here: https://www.johnsonfistel.com/investigations/altimmune-inc-2/. For more information, contact James Baker at (619) 814-4471 or jimb@johnsonfistel.com.
According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune’s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune’s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.
Johnson Fistel, PLLP | Top Law Firm for Securities Fraud and Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.
Achievements:
In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs’ securities law firm in the United States, as determined by the total dollar value of final recoveries.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
